Scientists find six new targets to wake immune cells against brain cancer

Glioblastoma kills most of its victims within 15 months. The cancer is so effective at hiding that standard immunotherapy — the drugs that teach immune cells to recognize and attack tumors — barely works at all.

Now researchers at MIT have figured out why, and they've identified six new angles of attack.

The problem isn't the cancer cells themselves. It's the immune cells that have been tricked into protecting them. Macrophages, which normally defend the body, get recruited into glioblastoma tumors and flip sides. They shield the cancer from T cells, the immune soldiers that would otherwise destroy it. It's a hostile takeover of your own defense system.

Forest White's team at the MIT Koch Institute wanted to understand how this betrayal happens — not just the end result, but the moment-by-moment evolution. They used advanced profiling tools to map how macrophages change when they encounter glioblastoma cells, and how the tumor cells themselves transform in response. "It's a little bit like what happens when a new family moves into a neighborhood," White explains. "The family members' lives change, but so do the social dynamics of the people around them."

What they found was intricate and revealing. Over 800 peptides in the macrophages shifted their expression when exposed to glioblastoma cells. Meanwhile, the tumor cells themselves rewired their surface — over 40 antigens that trigger immune responses suddenly appeared in higher numbers. These antigens are like flags that T cells could theoretically recognize and attack, if they could only see them.

The team narrowed the possibilities down to six of the most promising antigens. They built mRNA-based immunotherapies targeting these specific flags and tested them in mice. The results were striking: tumors slowed significantly, and in some cases disappeared entirely.

"This study demonstrates the promise of profiling cell surface antigens," says Yufei Cui, a PhD candidate in the White lab. "Our approach could be used to design improved immunotherapies against many cancer types."

The work is still early — mouse models don't always translate to human patients, and the team is planning further studies in live tumor systems. But the logic is sound: if you can identify what the cancer is hiding behind, you can teach the immune system to see through the disguise. The next phase will explore how dendritic cells, which act as messengers between tumor and immune system, might be leveraged to strengthen the response.

For glioblastoma patients, where five-year survival currently sits at 5%, a new set of targets means a new set of possibilities.